- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03573076
Treatment of Photodamaged Skin of the décolleté
Treatment of Photodamaged Skin of the décolleté With Fractional Laser, Radio-frequency Microneedling, and Photodynamic Therapy
Study Overview
Status
Conditions
Detailed Description
Photoaging of skin and actinic keratoses Photoaging of the skin is the result of UV radiation in chronic sun exposure and its deleterious effects. Photoaging includes fine and coarse wrinkles, roughness, laxity, mottled pigmentation, coarseness, sallowness, telangiectasia, solar lentigines and dysplastic actinic keratoses. The process can be of both cosmetic and medical importance. Actinic keratoses (AK) are common dysplastic pre-malignant lesions that may develop into a malign invasive squamous cell carcinomas (SCC). SCCs have metastatic potential at up to 3%. The risk of malign transformation from AK to SCC is highest in chronic sun-damaged skin with confluent field-cancerization from multiple AK. National guidelines recommend treatment of the entire field of sun damaged skin with photodynamic therapy and several topical drugs, e.g. imiquimod, diclofenac, ingenol mebutate, and 5-fluoruracil. Repeat treatments are usually necessary to achieve the desired results in patients with chronic sun damaged skin.
Photochemical treatment with photodynamic therapy
Photodynamic therapy (PDT) is a treatment that uses a photosensitizer drug activated in the skin by light in the visible spectrum. Methyl aminolevulinate (MAL) is a photosensitizing agent with great affinity for dysplastic cells, and transforms into the light-sensitive Protoporphyrin PpIX. When exposed to light, photoactivated PpIX catalyzes a reactive oxygen species reaction, which leads to irreversible cell apoptosis of the dysplastic or neoplastic tissue. PDT can be used as treatment of a wide range of photoaging skin defects including actinic keratoses, and is exceedingly well suited for treatment of larger skin areas. PDT produces cosmetically pleasing results in extension of the excellent AK clearance.
Physical intervention with fractional laser and light-based interventions
Fractional laser and light-based treatments with lasers and microneedles are approaches that can be applied very precisely, and can be used to rejuvenate photodamaged skin.
Laser-treatment for rejuvenation of skin can be achieved using a non-ablative 1927 nm fractionated thulium laser (NAFL), good results have been reported for many aspects of photoaging, and specifically for actinic keratoses with good results. The thulium laser works by creating vertical thermal laser-channels in the skin without the ablative effect to the epidermis. Laser-treatment with the thulium laser may be combined with other treatments like PDT to produce synergistic effects.
Microneedling (MN) is a treatment option in which the skin epidermis is penetrated by closely arranged multiple microneedles. This can induce collagen production and stimulate the release of growth factors, and collagen synthesis and remodeling, producing the effects of rejuvenation. Radio-frequency (RF) microneedling (MN), also known as RF-MN, adds RF making it possible for insulated needles to emit heat at the needle-heads when the epidermis is fully punctured, possibly enhancing the described effects even further. Good results have been reported using MN as skin rejuvenation, and can the treatment be used in conjunction with PDT.
The delicate skin of the décolleté is subject to a high amount of accumulated life-time sun exposure, and is thus highly susceptible to photoaging effects. A mild and effective treatment of photodamaged skin for this particular area is highly desirable, and may be achieved by developing new combination strategies, in which the thulium laser or a microneedling device can be used as effective pre-treatment for PDT. To our knowledge, no previous randomized study has compared the use of the non-ablative thulium laser or microneedling in combination with photodynamic treatment (PDT).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Copenhagen NV
-
Copenhagen, Copenhagen NV, Denmark, 2400
- Bispebjerg University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Décolleté with chronic field-change photodamaged skin.
- Area with visually homogenous photodamage.
- Provide informed written consent.
- Fertile women must provide a negative U-hCG pregnancy test at the time of inclusion, and use safe anticontraceptive during the entire study period, e.g. oral hormonal contraceptives, intrauterine devices, subdermal implantation, or hormonal vaginal ring.
Exclusion Criteria:
- Treatment of actinic keratoses in the décolleté area within the last 30 days.
- Porphyria.
- Pregnant or nursing women.
- Skin cancer (invasive, in situ), keratoacanthoma, or other infiltrating tumors in the study area.
- Known tendencies to produce hypertrophic scarring or keloids.
- Allergies against Metvix creme solution, peanuts, or soy.
- Considered unable to follow the study protocol, e.g. alcohol dependence syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Thulium laser + photodynamic therapy
Non-ablative Thulium laser (NAFL) + Photodynamic therapy combination treatment
|
Photodynamic therapy with Methyl Aminolevulinate creme and red light.
Non-ablative Thulium laser (NAFL).
|
Experimental: RF microneedles + photodynamic therapy
Radio-frequency microneedles (RF-MN) + Photodynamic therapy combination treatment
|
Photodynamic therapy with Methyl Aminolevulinate creme and red light.
Radio-frequency microneedles (RF-MN).
|
Active Comparator: Non-ablative Thulium laser
Non-ablative Thulium laser (NAFL) single treatment
|
Non-ablative Thulium laser (NAFL).
|
Active Comparator: RF microneedles
Radio-frequency microneedles (RF-MN) single treatment
|
Radio-frequency microneedles (RF-MN).
|
No Intervention: Control
Control receiving no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical improvement of photodamage
Time Frame: 12 weeks
|
5-point categorial scale of photodamage severity, measuring changes in skin texture, pigmentation, telangiectasia, and wrinkles.
Scores are 0, 1, 2, 3, and 4, for none, mild, moderate, severe, and very severe, respectively.
A reduction in score from initial scoring to post-treatment is desirable.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment effect on actinic keratoses
Time Frame: 12 weeks
|
Evaluated on the Olsen grading scale for actinic keratoses thickness.
Scores are 1, 2, and 3, for slightly palpable, moderately thick, and very thick and hyperkeratotic, respectively.
A reduction in score from initial scoring to post-treatment is desirable.
|
12 weeks
|
Severity of local skin reactions
Time Frame: 7 days
|
Local skin reaction (LSR)-grading scale. Evaluation of redness, scaling, edema, pustules, and erosion on a 5-point categorial scale of severity. Scores are 0, 1, 2, 3, and 4, for individual parameters: Redness: None, slightly pink <50%, pink or light red >50%, red restricted to treatment area, and red extending outside treatment area. Scaling: None, isolated scale, scaling <50%, scaling >50%, scaling extending outside treatment area. Edema: None, slight specific edema, palpable edema beyond individual lesions, confluent and/or visible edema, and marked swelling extending outside treatment area. Pustules: None, vesicles only, transudate or pustules <50%, transudate or pustules >50%, and transudate or pustules extending outside treatment area. Erosion: None, lesion specific erosion, erosion extending beyond individual lesion, erosion >50%, and black eschar or ulceration. |
7 days
|
Presence of perceived pain during treatment
Time Frame: 0 days
|
VAS Visual analogue scale for perceived pain.
Scores are 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, ranging from none to very severe.
Higher is worse, and lower scores for treatment modalities are desirable.
|
0 days
|
Cosmetic results
Time Frame: 12 weeks
|
Cosmetic results on a 5-point categorial scale for perceived cosmetic outcome compared with base starting point for the individual patient.
Scores are 0, 1, 2, 3, and 4, for poor, acceptable, good, excellent, and outstanding, respectively.
A higher score is desirable.
|
12 weeks
|
Protoporphyrin IX (PpIX) fluorescence uptake
Time Frame: 0 days
|
Levels of PpIX uptake in the skin computed quantitatively from PpIX imaging.
Imaging before application, after 3 hours, and after LED exposure.
|
0 days
|
Safety including wounding, scarring, hyper and hypo pigmentation
Time Frame: 12 weeks
|
Safety concerning side-effects evaluated on a 5-point categorial scale for hyper- and hypopigmentation, erosions, and scarring.
Scores are 0, 1, 2, 3, and 4, for none, mild, moderate, severe, and very severe.
A lower score is desirable.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Merete Haedersdal, MD, Bispebjerg Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2018-000189-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Photodamaged Skin
-
Universitas PadjadjaranActive, not recruitingPhotodamaged SkinIndonesia
-
Revision SkincareStephens & Associates, Inc.CompletedSkin Care | Photodamaged SkinUnited States
-
Bispebjerg HospitalTerminated
-
Goldman, Butterwick, Fitzpatrick and GroffBausch Health Americas, Inc.Active, not recruiting
-
Johns Hopkins UniversityCompletedWrinkles | Photodamaged SkinUnited States
-
RWTH Aachen UniversityCompleted
-
Austin Institute for Clinical ResearchSkinCeuticalsNot yet recruiting
-
PfizerCompleted
-
ScitonCompletedDyschromia | Photodamaged Skin
-
Galderma R&DActive, not recruitingPhotodamaged Skin | Volume Deficiency of the MidfaceUnited States
Clinical Trials on Photodynamic therapy
-
Centre Hospitalier Universitaire de NiceWithdrawnDystrophic Epidermolysis BullosaFrance
-
National Taiwan University HospitalCompleted
-
photonamic GmbH & Co. KGCompletedActinic KeratosisGermany
-
University of KansasDUSA Pharmaceuticals, Inc.CompletedHidradenitis SuppurativaUnited States
-
Northwestern UniversityCompleted
-
Bispebjerg HospitalCompletedActinic KeratosesDenmark
-
Bispebjerg HospitalCompleted
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Non-small Cell Lung Cancer | Stage 0 Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung CancerUnited States
-
Fujian Longhua Pharmaceutical Co. LtdSun Yat-sen University; Fuzhou UniversityUnknownEsophageal Cancer | Skin CancerChina
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedAggressive PeriodontitisBrazil